Doc Groups Seek To Block CMS Biosimilars Policy Via Congress
This article was originally published in The Pink Sheet Daily
Executive Summary
Letter from six physician organizations to Senate Finance Committee Chairman Hatch says CMS' decision to group multiple biosimilars into a single payment code undermines innovation, science and safety.